advertisement
Abstract #10135 Published in IGR 6-1
Long-term efficacy and safety of combined topical antiglaucoma therapy: timolol and unoprostone versus betaxolol and unoprostone
Ohtake Y; Tanino T; Kimura I; Mashima Y; Oguchi YNippon Ganka Gakkai Zasshi 2004; 108: 23-28
PURPOSE: To evaluate the long-term efficacy and safety of treatment combining topical beta-blockers and isopropyl unoprostone in primary open-angle glaucoma and normal-tension glaucoma patients. METHODS: A prospective, open-label, parallel-group clinical comparison trial was performed to evaluate efficacy and safety of treatment combining 0.5% betaxolol and 0.12% isopropyl unoprostone (B&U) or 0.5% timolol and 0.12% isopropyl unoprostone (T&U). Forty eyes of 40 patients, which were matched for age and stage of glaucomatous visual field defect, were studied. Twenty patients were treated with B&U and the other 20 with T&U twice daily for 24 months. Goldmann intraocular pressure (IOP), Humphrey automated perimetry, blood pressure, heart rate, and peak flow were performed every six months in each group. RESULTS: In the B&U treatment group, mean IOP was 21.2 mmHg at baseline and 18.3 mmHg (p < 0.005) after two years, and in the T&U treatment group, it was 21.1 mmHg at baseline and 17.9 mmHg (p < 0.001) after two years. MD values decreased over by 2 dB in one patient in the B&U treatment group and three in the T&U treatment group. The average MD value was significantly improved from -7.40 to -5.90 dB after two years with B&U treatment (p < 0.05), but no difference was seen with T&U treatment. None of the patients stopped combined therapy because of side effects, although heart rate was significantly reduced in the T&U treatment group only. CONCLUSIONS: Both combined treatments were effective for IOP reduction in glaucoma patients, and the data from the B&U group suggest that B&U was more effective in maintaining visual field than T&U. LA: Japanese
Dr. Y. Ohtake, Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
